Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
NYX (human)

Overview
NYX Defects in NYX are the cause of congenital stationary night blindness type 1A (CSNB1A); also called X- linked congenital stationary night blindness (XLCSNB). Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision. CSNB1A is characterized by impaired scotopic vision, myopia, hyperopia, nystagmus and reduced visual acuity. Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class IV subfamily. Note: This description may include information from UniProtKB.
Protein type: Secreted; Secreted, signal peptide
Chromosomal Location of Human Ortholog: Xp11.4
Cellular Component: cytoplasm; intracellular
Molecular Function: protein kinase inhibitor activity
Biological Process: cytokine and chemokine mediated signaling pathway; negative regulation of JAK-STAT cascade; negative regulation of protein kinase activity
Disease: Night Blindness, Congenital Stationary, Type 1a
Reference #:  Q9GZU5 (UniProtKB)
Alt. Names/Synonyms: CLRP; CSNB1; CSNB4; leucine-rich repeat protein; MGC138447; Nyctalopin; NYX
Gene Symbols: NYX
Molecular weight: 52,000 Da
Basal Isoelectric point: 9.1  Predict pI for various phosphorylation states
Select Structure to View Below

NYX

Protein Structure Not Found.


STRING  |  cBioPortal  |  Wikipedia  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  Pfam  |  Phospho.ELM  |  NetworKIN  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Modification Sites and Domains  

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment



 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 1 S92 LPSLRRLSLRHNNLS
0 1 S99 SLRHNNLSFITPGAF
0 1 T102 HNNLSFITPGAFKGL
0 1 Y284‑p LAELELLyLDRNSIA
0 1 S364‑p VTDVPCAsPGsVAGL
0 1 S367‑p VPCAsPGsVAGLDLS
0 2 T377‑p GLDLSQVtFGRSSDG
  mouse

 
S87‑p LPSLRRLsLRHNNLs
S94‑p sLRHNNLsFItPGAF
T97‑p HNNLsFItPGAFKGL
Y279 LAELELLYLDRNSIT
S359 VADVACASPGSVAGQ
S362 VACASPGSVAGQDLS
V372 GQDLSQVVFERSSDG
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.